The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: A pooled analysis of data from the pivotal trials

被引：13

作者：

Kane, John M. ^{[3
]}

Assuncao-Talbott, Sheila ^{[1
]}

Eudicone, James M. ^{[1
]}

Pikalov, Andrei ^{[2
]}

Whitehead, Richard ^{[2
]}

Crandall, David T. ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Plainsboro, NJ USA

[2] Otsuka Amer Pharmaceut Inc, Rockville, MD USA

[3] Zucker Hillside Hosp, New York, NY USA

来源：

SCHIZOPHRENIA RESEARCH | 2008年 / 105卷 / 1-3期

关键词：

Aripiprazole; Schizophrenia; Item analysis;

D O I：

10.1016/j.schres.2008.06.018

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Objective: To examine the efficacy of aripiprazole across symptoms in patients with acute exacerbation of schizophrenia or schizoaffective disorder. Methods: Data were pooled from five, 4-6-week acute studies. PANSS Total, Positive, Negative, and General Psychopathology Subscale improvements were analyzed, as well as all 30 individual PANSS items. Results: Aripiprazole had statistically significant decreases versus placebo on PANSS subscales at Week 4, similar to those seen with haloperidol. Aripiprazole-treated patients also showed significant decreases versus placebo in 26 of the 30 PANSS items (all P < 0.05). Conclusion: Aripiprazole demonstrates statistically and clinically significant efficacy across a range of symptoms in schizophrenia. (c) 2008 Published by Elsevier B.V.

引用

页码：208 / 215

页数：8

共 28 条

[1] Determinants of real-world functional performance in schizophrenia subjects: Correlations with cognition, functional capacity, and symptoms [J].